BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 30375700)

  • 1. CD33
    Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
    Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of monocytic myeloid-derived suppressor cells in endometriosis patients: A pilot study.
    Chen H; Qin S; Lei A; Li X; Gao Q; Dong J; Xiao Q; Zhou J
    Int Immunopharmacol; 2017 Jun; 47():150-158. PubMed ID: 28407569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD45
    Mao FY; Zhao YL; Lv YP; Teng YS; Kong H; Liu YG; Wu XL; Hao CJ; Chen W; Duan MB; Han B; Ma Q; Wang TT; Peng LS; Zhang JY; Cheng P; Su CY; Fu XL; Zou QM; Guo G; Guo XL; Zhuang Y
    Cell Death Dis; 2018 Jul; 9(7):763. PubMed ID: 29988030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
    Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
    J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
    J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.
    Lechner MG; Megiel C; Russell SM; Bingham B; Arger N; Woo T; Epstein AL
    J Transl Med; 2011 Jun; 9():90. PubMed ID: 21658270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive role of CD11b
    Hyun SY; Na EJ; Jang JE; Chung H; Kim SJ; Kim JS; Kong JH; Shim KY; Lee JI; Min YH; Cheong JW
    Cancer Med; 2020 Oct; 9(19):7007-7017. PubMed ID: 32780544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
    Zhang B; Wang Z; Wu L; Zhang M; Li W; Ding J; Zhu J; Wei H; Zhao K
    PLoS One; 2013; 8(2):e57114. PubMed ID: 23437326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthy myeloid-derived suppressor cells express the surface ectoenzyme Vanin-2 (VNN2).
    Soler DC; Kerstetter-Fogle A; Young AB; Rayman P; Finke JH; Debanne SM; Cooper KD; Barnholtz-Sloan J; Sloan AE; McCormick TS
    Mol Immunol; 2022 Feb; 142():1-10. PubMed ID: 34953280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
    Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.
    Höchst B; Schildberg FA; Sauerborn P; Gäbel YA; Gevensleben H; Goltz D; Heukamp LC; Türler A; Ballmaier M; Gieseke F; Müller I; Kalff J; Kurts C; Knolle PA; Diehl L
    J Hepatol; 2013 Sep; 59(3):528-35. PubMed ID: 23665041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
    Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
    Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFN-γ decreased the suppressive function of CD33
    Zhan X; Hu S; Wu Y; Li M; Liu T; Ming S; Wu M; Liu M; Huang X
    Mol Immunol; 2018 Feb; 94():107-120. PubMed ID: 29291452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles of polymorphonuclear myeloid-derived suppressor cells in endometriosis.
    Satake E; Koga K; Takamura M; Izumi G; Elsherbini M; Taguchi A; Makabe T; Takeuchi A; Harada M; Hirata T; Hirota Y; Wada-Hiraike O; Osuga Y
    J Reprod Immunol; 2021 Nov; 148():103371. PubMed ID: 34517223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-α-based treatment of patients with chronic HCV show increased levels of cells with myeloid-derived suppressor cell phenotype and of IDO and NOS.
    Salem ML; Zidan AA; Attia M; El-Naggar RE; Nassef M; Abou El-Azm AR; El-Bate H; Yussif M; Galal S; Abo Senna M; El Demellawy M
    Immunopharmacol Immunotoxicol; 2017 Aug; 39(4):188-198. PubMed ID: 28472907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD14
    Bernsmeier C; Triantafyllou E; Brenig R; Lebosse FJ; Singanayagam A; Patel VC; Pop OT; Khamri W; Nathwani R; Tidswell R; Weston CJ; Adams DH; Thursz MR; Wendon JA; Antoniades CG
    Gut; 2018 Jun; 67(6):1155-1167. PubMed ID: 28592438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
    Feng PH; Lee KY; Chang YL; Chan YF; Kuo LW; Lin TY; Chung FT; Kuo CS; Yu CT; Lin SM; Wang CH; Chou CL; Huang CD; Kuo HP
    Am J Respir Crit Care Med; 2012 Nov; 186(10):1025-36. PubMed ID: 22955317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating and tumor-infiltrating arginase 1-expressing cells in gastric adenocarcinoma patients were mainly immature and monocytic Myeloid-derived suppressor cells.
    Ren W; Zhang X; Li W; Feng Q; Feng H; Tong Y; Rong H; Wang W; Zhang D; Zhang Z; Tu S
    Sci Rep; 2020 May; 10(1):8056. PubMed ID: 32415175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
    Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
    Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The study of CD14+HLA-DR-/low myeloid-drived suppressor cell (MDSC) in peripheral blood of peripheral T-cell lymphoma patients and its biological function.
    Du J; Sun X; Song Y
    Cell Mol Biol (Noisy-le-grand); 2017 Mar; 63(3):62-67. PubMed ID: 28466815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.